ArticleAmerican journal of translational research2021
Triple-negative metaplastic breast cancer: treatment and prognosis by type of surgery.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.
- Breast conservation versus mastectomy for metaplastic breast cancer: A systematic review and meta-analysis.Asia-Pacific journal of clinical oncology · 2025Pooled it
- Development and validation of competitive risk model for older women with metaplastic breast cancer.BMC women's health · 2023Trial
- A retrospective study of metaplastic breast cancer: Treatment and prognosis through chemotherapy followed by radiotherapy.Medicine · 2026Article
- The Hippo Pathway in Metaplastic Breast Carcinoma: Prognostic Significance and Therapeutic Implications.Current issues in molecular biology · 2025Article
- Log odds of positive lymph nodes as a prognostic marker in resectable triple negative breast cancer.Scientific reports · 2025Article
- A case of high-grade adenosquamous carcinoma of the breast: case report and literature review.Frontiers in oncology · 2025Review
- The mixed subtype has a worse prognosis than other histological subtypes: a retrospective analysis of 217 patients with metaplastic breast cancer.Breast cancer research and treatment · 2023Article
- Prognostic Factor Analysis and Model Construction of Triple-Negative Metaplastic Breast Carcinoma After Surgery.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe role of surgery type in the prognosis of triple-negative metaplastic breast cancer (TN-MBC) patients remains controversial. Our study was designed to assess the role of surgery type in patient outcomes. MATERIALS AND
methodsData from the Surveillance, Epidemiology, and End Results database were extracted to analyze patients with TN-MBC between 2010 and 2016. Kaplan-Meier analyses and multivariate Cox proportional models were used to estimate the prognoses.
resultsWe included 1,146 patients with a median follow-up time of 26 months (range 1-83 months). 470 (41.0%), 369 (32.2%), 244 (21.3%), and 63 (5.5%) patients underwent breast-conserving surgery (BCS), total mastectomy (TM), radical mastectomy, or no surgery. With the multivariate Cox analysis, the prognosis was related to age, TNM stage, and surgery type. With the Kaplan-Meier analysis, the more radical the operation, the worse the prognosis for the patients in the entire cohort. Within stage I-III disease, the best prognoses were observed in the patients undergoing BCS, followed by TM and radical mastectomy. The adjusted survival analysis showed that the prognoses of the patients undergoing BCS were better than the prognoses of the patients undergoing TM. Within stage IV disease, the patients who underwent an operation had a better prognosis regardless of the mode.
conclusionPatients undergoing BCS had the best prognoses among the patients with early and locally advanced TN-MBC. This improves our understanding of the clinicopathological and prognostic features of this rare entity but also provides more convincing therapeutic guidelines for TN-MBC.
Indexed as
Identifiers
34786095PMC8581904W3212413116What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.